The New York powerhouse has agreed to surrender its 11.7% interest in the HIV-focused company for $1.875 billion. Under terms ...

Novavax said on Tuesday it signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses ...

Pfizer has signed a deal worth up to $530m with US-based vaccine technology company Novavax. This agreement will see Pfizer hand over $30m upfront for the non-exclusive rights to Novavax’s proprietary ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

Buying into it will quickly have you invested in 100 companies with at least 10 years of dividend increases. Top holdings ...

Novavax (NVAX) shares added ~5% in the premarket on Tuesday after the COVID-19 vaccine maker reached a licensing deal with ...

Britain's GSK and Japan's Shionogi said on Tuesday that Pfizer will exit their HIV specialist ViiV Healthcare in a deal that ...

Novavax ‌said on ‌Tuesday it was ⁠entering ‌into a ‍licensing agreement with ​Pfizer ‌to develop vaccine products ⁠for ...

Pfizer will relinquish its stake in ViiV Healthcare in a deal valued at just over $2.1 billion that ramps up Shionogi's ...

Any believers in UPS who buy now can enjoy a generous dividend payment every quarter while waiting for a turnaround. Given ...

The partnership brings together Pfizer’s scientific data and therapeutic expertise with Boltz’s open-source AI foundation ...

Novavax has agreed to a deal to let Pfizer use Matrix-M adjuvant in its products for an upfront payment of $30 million and up to another $500 million in milestone payments.